Citryll

Citryll is a Dutch biotech company focused on developing innovative treatments for autoimmune and other severe diseases such as lupus, vasculitis, pulmonary fibrosis, asthma, rheumatoid arthritis, and organ damage due to sepsis. The company targets the pathobiology of neutrophil extracellular traps (NETs), which are networks of extracellular fibers composed of DNA from neutrophils, a type of white blood cell. By inhibiting the source of autoantigens and NET-derived toxic molecules, Citryll aims to provide a more targeted approach to treatment, avoiding the broad targeting of inflammation or acquired immunity.

Citryll operates in the biopharmaceutical market, primarily serving patients with autoimmune and inflammatory diseases. The company's business model involves the research, development, and commercialization of therapeutic antibodies. Citryll makes money through the development and eventual sale of its proprietary treatments, as well as potential partnerships and licensing agreements with larger pharmaceutical companies.

Citryll's lead product, CIT-013, is currently in the development phase, with first human dosing planned as part of a Single Ascending Dose (SAD) study in healthy volunteers. The company collaborates with partners like Lonza for GMP production and formulation of the antibody.

Keywords: biotech, autoimmune diseases, neutrophil extracellular traps, lupus, vasculitis, pulmonary fibrosis, asthma, rheumatoid arthritis, sepsis, therapeutic antibodies.